SAGE Sage Therapeutics, Inc.

Nasdaq sagerx.com


$ 8.69 $ -0.02 (-0.23 %)    

Wednesday, 30-Jul-2025 19:44:43 EDT
QQQ $ 602.18 $ 4.22 (0.71 %)
DIA $ 462.40 $ 0.00 (0 %)
SPY $ 664.99 $ 2.94 (0.44 %)
TLT $ 90.78 $ -0.20 (-0.22 %)
GLD $ 387.26 $ 6.60 (1.73 %)
$ 8.68
$ 8.74
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 4.62 - $ 11.44
22,698,684
na
544.97M
$ 1.14
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-30-2025 06-30-2025 10-Q
2 04-29-2025 03-31-2025 10-Q
3 02-11-2025 12-31-2024 10-K
4 10-29-2024 09-30-2024 10-Q
5 07-31-2024 06-30-2024 10-Q
6 04-25-2024 03-31-2024 10-Q
7 02-14-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-02-2023 03-31-2023 10-Q
11 02-16-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-02-2022 06-30-2022 10-Q
14 05-03-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 05-04-2021 03-31-2021 10-Q
19 02-24-2021 12-31-2020 10-K
20 11-05-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-07-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-02-2019 03-31-2019 10-Q
27 02-19-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 02-22-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-03-2017 06-30-2017 10-Q
34 05-10-2017 03-31-2017 10-Q
35 02-24-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-09-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ:SUPN) ("Supernus", and the "Company"), today ann...

 scotiabank-downgrades-sage-therapeutics-to-sector-perform-lowers-price-target-to-92

Scotiabank analyst George Farmer downgrades Sage Therapeutics (NASDAQ:SAGE) from Sector Outperform to Sector Perform and low...

 baird-maintains-neutral-on-sage-therapeutics-raises-price-target-to-9

Baird analyst Joel Beatty maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and raises the price target from $7 to $9.

 piper-sandler-downgrades-sage-therapeutics-to-neutral-lowers-price-target-to-85

Piper Sandler analyst David Amsellem downgrades Sage Therapeutics (NASDAQ:SAGE) from Overweight to Neutral and lowers the pr...

 truist-securities-maintains-hold-on-sage-therapeutics-raises-price-target-to-9

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and raises the price target from $8...

 hc-wainwright--co-reiterates-neutral-on-sage-therapeutics-maintains-12-price-target

HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $12 pri...

 canaccord-genuity-maintains-hold-on-sage-therapeutics-raises-price-target-to-85

Canaccord Genuity analyst Sumant Kulkarni maintains Sage Therapeutics (NASDAQ:SAGE) with a Hold and raises the price target ...

 us-stock-futures-tumble-after-trump-threatens-real-end-to-irans-nuclear-problem-avoid-getting-whipsawed-by-noise-says-expert

U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower...

 supernus-pharma-acquires-maker-of-postpartum-depression-drug-zurzuvae-in-795-million-deal

Supernus to acquire Sage Therapeutics for $795 million, gaining Zurzuvae and aiming for $200 million in annual cost synergies b...

 needham-reiterates-hold-on-sage-therapeuticsto-hold

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) from Hold to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION